[Skip to Navigation]
April 1985

Serum Angiotensin-Converting Enzyme Activity: Its Use in the Evaluation and Management of Hypercalcemia Associated With Sarcoidosis

Author Affiliations

From the Departments of Internal Medicine (Drs DeRemee and Lufkin), Thoracic Diseases (Drs DeRemee and Rohrbach), Endocrinology (Dr Lufkin), and Cell Biology (Dr Rohrbach), Mayo Clinic, and the Mayo Medical School (Drs DeRemee, Lufkin, and Rohrbach), Rochester, Minn.

Arch Intern Med. 1985;145(4):677-679. doi:10.1001/archinte.1985.00360040099022

• Serum angiotensin-converting enzyme (SACE) was measured in 14 patients (eight women and six men) with sarcoidosis and hypercalcemia. Thirteen patients were treated with prednisone, and 12 achieved normal or nearly normal serum calcium values. Two patients had coexistent hyperparathyroidism. Seven of eight patients with serial SACE measurements exhibited parallel falls in SACE and serum calcium levels. Eleven patients were successfully treated with alternate-day prednisone regimens. The data suggest that serial SACE measurements are useful in the evaluation and management of sarcoidosis with hypercalcemia. In patients with sarcoidosis, the reduction of SACE levels during glucocorticoid treatment may be due to a suppression of granuloma formation. Concomitant falls in serum calcium level suggest an important role of the granuloma or its cellular precursors in vitamin D metabolism.

(Arch Intern Med 1985;145:677-679)

Hypercalcemia occurs in sarcoidosis with variable frequency, estimated from 5% to 10% of cases. At times, hypercalcemia may be the